- Trials with a EudraCT protocol (310)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
310 result(s) found for: Acid value.
Displaying page 1 of 16.
EudraCT Number: 2016-002217-22 | Sponsor Protocol Number: SJ-546 | Start Date*: 2016-09-02 | ||||||||||||||||
Sponsor Name:Sjællands University Hospital, Køge | ||||||||||||||||||
Full Title: Validation of stimulated ∆FGF19 for diagnosing bile acid diarrhoea | ||||||||||||||||||
Medical condition: Bile acid malabsorption / bile acid diarrhoea | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000638-35 | Sponsor Protocol Number: CZOL446N2312 | Start Date*: 2004-09-15 |
Sponsor Name:Novartis Sverige AB | ||
Full Title: A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12... | ||
Medical condition: Postmenopausal Osteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004321-95 | Sponsor Protocol Number: AMLSG 07-04 | Start Date*: 2005-05-26 |
Sponsor Name:University of Ulm | ||
Full Title: RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATI... | ||
Medical condition: newly diagnosed acute myeloid leukemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002302-18 | Sponsor Protocol Number: POM-CL-201 | Start Date*: 2009-02-16 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: An open-label, multicenter, study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of three dosing regimens of oral AT2220 in patients with Pompe disease | |||||||||||||
Medical condition: Pompe Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014446-28 | Sponsor Protocol Number: JANUS | Start Date*: 2009-12-03 | |||||||||||
Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO | |||||||||||||
Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER | |||||||||||||
Medical condition: invasive prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001151-40 | Sponsor Protocol Number: CTU148N | Start Date*: 2019-07-09 |
Sponsor Name:RIEMSER Pharma GmbH | ||
Full Title: Phase II pilot study: To determine an effective and tolerable dose of Hylase® "Dessau" (bovine hyaluronidase) in the treatment of hyaluronic acid filler overshoots by injection into defined areas o... | ||
Medical condition: In this study, healthy subjects get an artificial over-injection with Hyaluron acid filler on the back of the hands. To demonstrate the effectiveness of hylase® "Dessau" as an antidote for hyaluro... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-002759-42 | Sponsor Protocol Number: AGLU02704 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Myozyme, Recombinant Human Acid alpha-Glucosidase (rhGAA), Treatmen... | |||||||||||||
Medical condition: Glycogen Storage Disease type II (Pompe's disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001443-63 | Sponsor Protocol Number: 01062 | Start Date*: 2006-07-10 |
Sponsor Name:European Lung Cancer Working Party | ||
Full Title: A phase II study assessing the activity of valproate acid plus doxorubicin in refractory or recurrent malignant mesothelioma. | ||
Medical condition: This is a prospective phase II study investigating well-known antimetabolite (doxorubicin) and antiepileptic (valproate) drugs, in combination, for the treatment of refractory or recurrent malignan... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005001-31 | Sponsor Protocol Number: CGV222 | Start Date*: 2014-03-25 | |||||||||||
Sponsor Name:Dra. Carmen Gómez Vaquero (Servicio de Reumatología del Hospital Universiari de Bellvitge - Idibell) | |||||||||||||
Full Title: Randomized clinical trial on the prevention of radiographic progression with zoledronic acid in patients with early rheumatoid arthritis and low disease activity | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000257-22 | Sponsor Protocol Number: D9612L00104 | Start Date*: 2006-07-03 |
Sponsor Name:AstraZeneca UK Ltd | ||
Full Title: A study to assess the effectiveness of esomeprazole 40 mg once daily in subjects with continuing gastroesophageal reflux disease (GORD) symptoms following treatment with a previous full dose proton... | ||
Medical condition: Gastroesophageal Reflux Disease (GORD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001762-13 | Sponsor Protocol Number: 747-401 | Start Date*: 2018-08-01 |
Sponsor Name:Intercept Pharmaceuticals, Inc. | ||
Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa... | ||
Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000539-42 | Sponsor Protocol Number: RB2-NL-1518 | Start Date*: 2016-04-15 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th... | ||
Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005710-34 | Sponsor Protocol Number: Acide_Tranexamique | Start Date*: 2022-02-21 | |||||||||||
Sponsor Name:Polyclinique Jean Villar - Bruges | |||||||||||||
Full Title: Benefits on post-operative pain of intraoperative tranexamic acid administration during shoulder arthroscopy. | |||||||||||||
Medical condition: Shoulder arthroscopy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003792-52 | Sponsor Protocol Number: PAAI04 | Start Date*: 2011-04-19 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik fuer Dermatologie | ||
Full Title: Azelaic acid iontophoresis versus topical azelaic acid cream in the treatment of melasma – An open randomized, controlled, prospective, single blinded clinical trial | ||
Medical condition: clinical diagnosis of melasma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002838-30 | Sponsor Protocol Number: IRST185.01 | Start Date*: 2008-08-22 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | |||||||||||||
Full Title: Phase II, randomized, multicentric study of docetaxel and zoledronic acid versus zoledronic acid in patient with prostate cancer and bone metastase treated with LHRH | |||||||||||||
Medical condition: Advanced prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000039-33 | Sponsor Protocol Number: 2018-06-017 | Start Date*: Information not available in EudraCT |
Sponsor Name:Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche | ||
Full Title: Multicentric, double-blind, randomized study to show that the addition of IV tranexamic acid versus placebo in ACL ligamentoplasties leads to a decrease in blood loss and postoperative pain | ||
Medical condition: Patients undergoing primary ACL ligamentoplasty with hamstring tendon removal on an outpatient basis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004047-25 | Sponsor Protocol Number: ALGMYL08718 | Start Date*: 2021-07-27 | |||||||||||
Sponsor Name:Sanofi(China) Investment Co Ltd, Shanghai Branch | |||||||||||||
Full Title: A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa Treatment | |||||||||||||
Medical condition: Infantile-Onset Pompe Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004552-37 | Sponsor Protocol Number: 18CH052 | Start Date*: 2019-05-07 | |||||||||||
Sponsor Name:CHU SAINT-ETIENNE | |||||||||||||
Full Title: Dose Study of Tranexamic Acid in Total Hip Replacement to Reduce Postoperative Hemoglobin Loss. A Phase 2 Randomized Double-blind Monocentric Study | |||||||||||||
Medical condition: Arthropathy of Hip | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000755-40 | Sponsor Protocol Number: ATB200-03 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Algluc... | |||||||||||||
Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) SE (Completed) HU (Completed) BE (Completed) SK (Completed) ES (Completed) NL (Completed) BG (Prematurely Ended) SI (Completed) GR (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000535-18 | Sponsor Protocol Number: ML17632 | Start Date*: 2005-05-18 |
Sponsor Name:Roche Pharma (Schweiz) AG | ||
Full Title: Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer. | ||
Medical condition: The target population for this trial are female patients with primary breast cancer with metastatic bone disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
